Akari Therapeutics PLC expected to post a loss of 11 cents a share - Earnings Preview

Akari Therapeutics

15/08/2025 21:42

Akari Therapeutics PLC AKTX.OQ AKTX.O is expected to  report results for the period ending September 30 2025

​LSEG's mean analyst estimate for Akari Therapeutics PLC is for a loss of 11 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The average consensus recommendation for the pharmaceuticals peer group is also "Buy".​

Wall Street's median 12-month price target for Akari Therapeutics PLC is $6.00, about 83.8% above its last closing price of $0.97

This summary was machine generated August 15 at 20:42 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)